<code id='55761F3EFF'></code><style id='55761F3EFF'></style>
    • <acronym id='55761F3EFF'></acronym>
      <center id='55761F3EFF'><center id='55761F3EFF'><tfoot id='55761F3EFF'></tfoot></center><abbr id='55761F3EFF'><dir id='55761F3EFF'><tfoot id='55761F3EFF'></tfoot><noframes id='55761F3EFF'>

    • <optgroup id='55761F3EFF'><strike id='55761F3EFF'><sup id='55761F3EFF'></sup></strike><code id='55761F3EFF'></code></optgroup>
        1. <b id='55761F3EFF'><label id='55761F3EFF'><select id='55761F3EFF'><dt id='55761F3EFF'><span id='55761F3EFF'></span></dt></select></label></b><u id='55761F3EFF'></u>
          <i id='55761F3EFF'><strike id='55761F3EFF'><tt id='55761F3EFF'><pre id='55761F3EFF'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:explore    - browse:7
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus